JW

Jörg Willuda

UZ Universitat Zurich: 3 patents #31 of 394Top 8%
SC Schering: 2 patents #1,083 of 2,442Top 45%
BH Bayer Healthcare: 1 patents #4,623 of 8,007Top 60%
BP Bayer Pharma: 1 patents #440 of 819Top 55%
SG Seattle Genetics: 1 patents #65 of 101Top 65%
DK Deutsches Krebsforschungszentrum: 1 patents #118 of 345Top 35%
📍 Schönfließ, DE: #4 of 6 inventorsTop 70%
Overall (All Time): #477,931 of 4,157,543Top 15%
10
Patents All Time

Issued Patents All Time

Showing 1–10 of 10 patents

Patent #TitleCo-InventorsDate
12221479 Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies Mark Trautwein, Rienk Offringa, Hans-Henning BÖHM, Philipp Beckhove 2025-02-11
11866495 Anti-CEACAM6 antibodies and uses thereof Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld +7 more 2024-01-09
11773164 Anti-CEACAM6 antibodies and uses thereof Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld +7 more 2023-10-03
10584167 Anti-CEACAM6 antibodies and uses thereof Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld +7 more 2020-03-10
8992932 Binder-drug conjugates (ADCs) and use thereof Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Charlotte Christine Kopitz, Joachim Schuhmacher +12 more 2015-03-31
8137932 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment Andreas Plückthun, Annemarie Honegger 2012-03-20
7858088 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment Andreas Plückthun, Annemarie Honegger 2010-12-28
7335775 Effector conjugates, process for their production and their pharmaceutical use Markus Berger, Gerhard Siemeister, Ulrich Klar, Andreas Menrad, Klaus Bosslet 2008-02-26
7129254 Effector conjugates, process for their production and their pharmaceutical use Markus Berger, Gerhard Siemeister, Ulrich Klar, Andreas Menrad, Klaus Bosslet 2006-10-31
7033798 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment Andreas Plückthun, Annemarie Honegger 2006-04-25